Compare OZ & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OZ | IKT |
|---|---|---|
| Founded | 2020 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 245.7M | 240.1M |
| IPO Year | 2020 | 2020 |
| Metric | OZ | IKT |
|---|---|---|
| Price | $56.00 | $1.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 18.6K | ★ 1.3M |
| Earning Date | 05-19-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.76 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,187,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $33.33 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 243.44 | N/A |
| 52 Week Low | $48.50 | $1.33 |
| 52 Week High | $69.00 | $2.37 |
| Indicator | OZ | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 62.10 | 47.70 |
| Support Level | $49.78 | $1.43 |
| Resistance Level | $57.35 | $1.88 |
| Average True Range (ATR) | 2.11 | 0.12 |
| MACD | 0.21 | -0.01 |
| Stochastic Oscillator | 78.71 | 35.29 |
Belpointe PREP LLC is a qualified opportunity fund. The company's investments consist of properties located in qualified opportunity zones for the development or redevelopment of multifamily, student housing, senior living, healthcare, industrial, self-storage, hospitality, office, mixed-use, data centers, and solar projects located throughout the United States and its territories. Company currently has two reporting segments, commercial: includes properties such as office, retail centers, and warehouses; and mixed-use: includes properties that blend both residential and retail components within a single real estate asset.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.